Rasagiline in Parkinson's disease: the show must go on

By Jost Wolfgang H  

Expert Opinion on Drug Safety, Vol. 12, Iss. 6, 2013-11 ,pp. : 797-800

Informa Healthcare

Access to resources Recommend Favorite

Antihypertensive therapy must be tailored to the individual in order to achieve blood pressure goals and reduce cardiovascular risk

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 23, Iss. 1, 2007-01 ,pp. : 7-9

Adis International

Access to resources Recommend Favorite

Lipoprotein-Associated Phospholipase A2: How Effective as a Risk Marker of Cardiovascular Disease and as a Therapeutic Target?

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 10, Iss. 4, 2011-01 ,pp. : 236-246

Bentham Science Publishers

Access to resources Recommend Favorite

Lipoprotein-associated phospholipase A₂: a novel marker of cardiovascular risk and potential therapeutic target

By Macphee Colin   Benson G Martin   Shi Yi   Zalewski Andrew  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 671-679

Informa Healthcare

Access to resources Recommend Favorite

Emerging Strategies and Agents to Lower Cardiovascular Risk by Increasing High Density Lipoprotein Cholesterol Levels

By  

Current Medicinal Chemistry, Vol. 16, Iss. 2, 2009-01 ,pp. : 144-156

Bentham Science Publishers

Access to resources Recommend Favorite